Pulse Biosciences Inc
Avatud
SektorTervishoid
25.84 6.12
Ülevaade
Aktsiahinna muutus
24h
Min
24.35
Max
26.13
Sissetulek | -1.1M -19M |
|---|---|
Müük | 137K 401K |
Aktsiakasum | -0.241 |
Kasumimarginaal | -4,633.666 |
Töötajad | 116 |
EBITDA | -1.4M -19M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +27.21% upside |
Järgmine tulemuste avaldamine | 11. aug 2026 |
|---|
Turukapital | 179M 1.7B |
|---|---|
Eelmine avamishind | 19.72 |
Eelmine sulgemishind | 25.84 |
Uudiste sentiment
By Acuity
34%
66%
94 / 342 Pingereas Healthcare
Pulse Biosciences Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Ettevõttest Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
